Matthew Kennedy

Bio:

Matt Kennedy PhD (AVP, Merck Neuroscience and Neuroimmunology lead) is a pharmacologist specializing in disease modifying therapies for neurodegenerative diseases. At Merck, he co-led the discovery of the BACE inhibitor, verubecestat (MK-8931), for Alzheimer’s disease and has built a Neuroimmunology team that has advanced multiple programs into clinical development for Alzheimer’s and Parkinson’s diseases. Developing translational biomarker strategies to improve clinical decision making and patient stratification is a core focus.  Matt serves on the Parkinson’s disease Foundation scientific advisory board and has received awards for his research and mentorship. He holds a PhD in Pharmacology from Vanderbilt University with postdoctoral work at the Mayo Clinic and Boston Children’s Hospital as a Howard Hughes Medical Institute Fellow.